Detalles de la búsqueda
1.
Accessory spleens recapitulate the immune microenvironment of the main spleen in immune thrombocytopenia.
Br J Haematol
; 202(1): 147-152, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36916680
2.
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study.
Blood
; 135(8): 534-541, 2020 02 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-31877211
3.
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study.
Haematologica
; 107(10): 2356-2364, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35385922
4.
Second primary malignancy in myelofibrosis patients treated with ruxolitinib.
Br J Haematol
; 193(2): 356-368, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33222197
5.
Nilotinib-induced bone marrow CD34+/lin-Ph+ cells early clearance in newly diagnosed CP-Chronic Myeloid Leukemia: Final report of the PhilosoPhi34 study.
Eur J Haematol
; 107(4): 436-448, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-34139044
6.
Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19.
Cancer
; 126(23): 5069-5076, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910456
7.
Low levels of ADAMTS-13 with high anti-ADAMTS-13 antibodies during remission of immune-mediated thrombotic thrombocytopenic purpura highly predict for disease relapse: A multi-institutional study.
Am J Hematol
; 95(8): 953-959, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32350923
8.
The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
Cancer
; 125(10): 1674-1682, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30707758
9.
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib.
Ann Hematol
; 98(4): 889-896, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30515542
10.
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
Cancer
; 124(10): 2228-2237, 2018 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-29499087
11.
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients.
Br J Haematol
; 183(1): 35-46, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30010187
12.
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients.
Hematol Oncol
; 2018 Apr 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29624703
13.
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers.
Am J Hematol
; 93(1): 58-64, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28983953
14.
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia.
Haematologica
; 102(9): 1530-1536, 2017 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-28572163
15.
Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients.
Haematologica
; 101(10): 1200-1207, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27470600
16.
Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia.
Am J Hematol
; 91(6): 617-22, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-26971721
17.
Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study.
Blood
; 132(5): 547-550, 2018 08 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29898955
18.
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia.
Haematologica
; 100(9): 1146-50, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-26113419
19.
Deferasirox in the management of iron-overload in patients with myelofibrosis: a multicentre study from the Rete Ematologica Lombarda (IRON-M study).
Br J Haematol
; 186(5): e123-e126, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31106402
20.
Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Haematologica
; 104(10): e470-e473, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-30846501